Author name: Yali Friedman

Biotech’s Longer Convalescence “The biotech sector has fallen, and it doesn’t seem able to get up. “

China: how to seize “commanding point” of biotechnology “China’s capital investment in the scientific research of life science is far

China: how to seize “commanding point” of biotechnology “China’s capital investment in the scientific research of life science is far

Stem-Cell Cash on a Winding Road They may not be investing in the companies themselves, but venture capitalists haven’t completely

Financial Snapshot For June 2004 Lackluster Performance

ImClone Hammered as Sales Lag Estimates Scandal-plagued ImClone Systems may have fallen off the road to recovery. While the company’s

Wanted: Drugs to Fight Bioterror “Amid new warnings about a possible summer of terror, the U.S. government is preparing to

Eco-Terror Cited as Top Threat Law enforcement officials warn that biotechnology firms, particularly those that conduct research on animals, must

The Drug Research War “Mention the term ‘outsourcing,’ and drug development probably doesn’t leap to mind. But this market, which

Biotechs struggle as IPOs find cool reception “Five initial public offerings had trading debuts Thursday, bringing mixed results and a